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British authorities have handed
the second ever licence for
therapeutic cloning to the creator
of Dolly the sheep for research
into motor neuron disease.
Meanwhile, the United Nations
keep struggling for an
international agreement that sorts
the acceptable cloning practices
from the unacceptable ones. 
The physicist Stephen Hawking
may well be the most famous
patient with motor neuron disease
(MND, also known as amyotrophic
lateral sclerosis, ALS), but he is by
no means a typical one. While he
has been living with the disease
for over four decades,
deteriorating only slowly, most
patients die within two years after
diagnosis. In the UK alone, there
are around 5,000 people affected
by the disease, with a mortality of
around three per day. Although
one gene has been identified in
connection with MND, it only
accounts for a small percentage
of cases, such that the disorder,
first described in 1869, remains
poorly understood and untreatable
to this day.
In the UK, the Human
Fertilisation and Embryology
Authority (HFEA) has now
permitted a team led by Ian
Wilmut at the Roslin Institute, near
Edinburgh, famous for creating
Dolly the cloned sheep, to use
therapeutic cloning to find out
more about this disease. In
collaboration with MND expert
Christopher Shaw at King’s
College, London, Wilmut is
planning to transfer nuclei from
MND patients who do not carry
the gene defect already known to
cause the disease into donor
eggs, and to generate stem cell
lines from them. Differentiating the
stem cells into motor neuron cells,
Wilmut is hoping to generate an in
vitro model of the disease, which
could allow researchers to track
down its elusive causes and
mechanisms.
The Roslin Institute has been a
leading centre in animal cloning
for nearly a decade, and has
recently begun to use its
experience in mammalian
reproduction to take up studies of
human embryology. It was among
the first institutions in Britain to
obtain a licence to generate stem
cell lines. Last September, when it
applied for permission to clone
MND-carrying embryos to
generate stem cells from them, it
ventured deeper into the field of
human cloning. However,
considering the severity of the
disease in question, the promise
of the proposed research, and the
track record of Wilmut and his
institute, there was very little
debate. The minutes of the HFEA
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Clone power: Ian Wilmut at the Roslin Institute, near Edinburgh, who helped create
Dolly the cloned sheep, has now got the go ahead to use cloning technology to study
motor neuron disease. (Picture: Science Photo Library.)
meeting only reveal suggestions
on a couple of very minor points
of presentation.
This is the second licence the
HFEA has granted for so-called
therapeutic cloning (even though
in these instances the
“therapeutic” effect will be rather
indirect). The first licence of this
kind went to the Newcastle
“Centre for Life”, where Alison
Murdoch and Miodrag Stojkovic
are trying to develop a cure for
type I (juvenile) diabetes. On top
of that, there are a handful of
institutions with licences to
generate new stem cell lines from
embryos left over after IVF
treatment, including King’s
college, Roslin, and Newcastle
(Curr. Biol. (2004) 14, R592). All
this makes the UK the undisputed
leading force in stem cell research
in Europe, and very competitive
on the global stage.
This role is made possible by a
generally supportive political
climate. The government supports
stem cell research with significant
funding, and public criticism of
the latest HFEA decision remained
confined to the religious quarters.
While Britain continues to
experience fierce protests against
animal experimentation, there is
much less concern about issues
like stem cells and cloning than
there is in European countries like
Germany and Switzerland (see
Curr. Biol. (2004) 14, R732, and
Curr. Biol. (2005) 15, R35,
respectively). And in the US,
President Bush has sanctioned
federal funding for only a few
established lines of human-
embryo-derived stem cells. In the
country’s submission to the UN
debate late last year, Susan Moore,
a US special adviser, told the
committee: “A ban that
differentiates between human
reproductive and experimental
cloning would essentially authorise
the creation of a human embryo for
the purpose of destroying it, thus
elevating the value of research and
experimentation above that of a
human life.”
She said the US supported
efforts to find breakthrough
treatment and cures for disease
but that it felt scientific progress
was possible without posing “a
threat to human dignity”. 
Belgium offered a compromise
proposal, cosponsored by the UK
and 19 other countries, that would
offer nations three options for
dealing with therapeutic cloning: a
ban, a moratorium or national
legislation to prevent misuse.
But after nearly three decades
of IVF, many people appear to
have grown familiar with the idea
of scientists handling early
embryos. What has remained a
taboo, however, is reproductive
cloning. In announcing the licence
for the Roslin Institute, the HFEA
has emphasized that cloning to
produce babies (and, indeed,
growing cloned embryos beyond
the stage that is necessary for the
sampling of embryonal stem cells)
remains illegal in the UK. In a
statement issued by the Royal
Society, Oxford zoologist Richard
Gardner, who chairs the society’s
working group on stem cells and
cloning, linked the issues of
therapeutic and reproductive
cloning by saying: “The granting
of a second licence in the UK to
carry out valuable research into
therapeutic cloning highlights the
potential benefits that are being
pursued through this new
technology. However, we do need
to ensure that mavericks do not
attempt to use this to undertake
reckless experiments in the
reproductive cloning of humans.”
Ensuring exactly this is what the
United Nations have been trying
for several years now. At the end
of 2003, an attempt to establish
an international convention
against cloning failed as around
40 countries including the US
supported a proposal from Costa
Rica that would have banned
therapeutic cloning along with the
reproductive kind (Curr. Biol.
(2003) 13, R937).
At the time of writing, the UN
committees are debating a new
draft proposal suggested by Italy,
which manages to leave the issue
of therapeutic cloning in the blur
of interpretation. The key
declaration reads in full: “Member
states are called upon to prohibit
any attempts to create human life
through cloning processes and
any research to achieve that aim.”
Now, are Wilmut and his
colleagues going to “create
human life” in their MND
research? The researchers would
probably deny that, while religious
campaigners could use this
sentence to support their call to
ban therapeutic cloning.
While the UN debate looks set to
carry on for some time,
researchers at Roslin will soon
write history by creating stem cell
lines carrying MND. While they are
at it, they might consider asking
Stephen Hawking for a few skin
cells. Even though he is an
extremely atypical case, the secret
of his long-term survival might be
written somewhere in his genes.
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High profile: Physicist Stephen Hawking is one of the most famous patients with
motor neuron disease. It is now under study with therapeutic cloning. (Photo: Science
Photo Library.)
